Livestrong Foundation

Livestrong Foundation

The foundation was established by Lance Armstrong in 1997 following his own diagnosis, with the initial mandate to fund cancer research and support programs. The wealth origin is tied directly to Armstrong's cycling career and the subsequent licensing of the iconic yellow wristband, which generated over $100 million in its peak years. Candice Aaron serves as Chair of the Board and Joseph Aragona, co-founder of Austin Ventures, is Vice Chair; Armstrong holds the title Board Emeritus after stepping away from active governance in 2012. The $23 million endowment (Altss estimate) is managed with a venture-adjacent posture, listing strategies from early-stage seed to buyout and secondaries. Beyond pure grantmaking, the foundation has historically held assets including convertible promissory notes. Core programmatic spending is directed toward free cancer-support services — fertility preservation, fitness programs, and emotional-health resources — rather than funding external labs. Austin remains the operational hub, with the foundation partnering locally with the Dell Medical School to run the Livestrong Cancer Institutes. Joseph Aragona's presence on the board bridges the nonprofit world to the venture ecosystem; he was a former chairman of the National Venture Capital Association and co-founded Austin Ventures, one of the region's most active investment firms. The office sits at 623 W. 38th Street in central Austin, after selling its prior East 6th Street headquarters to Notley Ventures, a social-impact investment group. There is no public record of affiliated philanthropic vehicles or family-office structures sitting alongside the foundation. Livestrong's structural differentiator is its post-founder brand persistence. After Armstrong's 2012 departure from the board, the organization maintained its program delivery without a comparable celebrity endowment — relying on a scaled-down, disciplined budget and a model where the foundation operates patient-facing support programs directly rather than functioning solely as a grantmaking endowment. This hybrid operating-foundation posture distinguishes it from other disease-focused nonprofits that outsource service delivery entirely.